Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
← catalyst calendarNCT04528082 · readout in 1,268 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
60estimated
Sites
27
Countries
France, Greece, Israel +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-09 | actual | When the study began enrolling |
| Primary completion | 2030-02-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-17 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Behçet Disease
Interventions
- Drug: Apremilast — also filed as Otezla®
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFArea Under the Curve for the Number of Oral Ulcers from Week 0 Through Week 12 (AUCw0-12)
measured Week 0 to Week 12
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed